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ABSTRACT African animal trypanosomosis (AAT) is caused by the tsetse fly-transmitted
protozoans Trypanosoma congolense and T. vivax and leads to huge agricultural losses
throughout sub-Saharan Africa. Three drugs are available to treat nagana in cattle (dimi-
nazene diaceturate, homidium chloride, and isometamidium chloride). With increasing
reports of drug-resistant populations, new molecules should be investigated as potential
candidates to combat nagana. Dicationic compounds have been demonstrated to have
excellent efficacy against different kinetoplastid parasites. This study therefore evaluated
the activities of 37 diamidines, using in vitro and ex vivo drug sensitivity assays. The 50%
inhibitory concentrations obtained ranged from 0.007 to 0.562 g/ml for T. congolense
and from 0.019 to 0.607 g/ml for T. vivax. On the basis of these promising re-
sults, 33 of these diamidines were further examined using in vivo mouse models
of infection. Minimal curative doses of 1.25 mg/kg of body weight for both T.
congolense- and T. vivax-infected mice were seen when the diamidines were ad-
ministered intraperitoneally (i.p.) over 4 consecutive days. From these observa-
tions, 15 of these 33 diamidines were then further tested in vivo, using a single
bolus dose for administration. The total cure of mice infected with T. congolense
and T. vivax was seen with single i.p. doses of 5 and 2.5 mg/kg, respectively.
This study identified a selection of diamidines which could be considered lead
compounds for the treatment of nagana.
KEYWORDS chemotherapy, diamidines, nagana, Trypanosoma, in vitro drug
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Trypanosoma congolense (subgenus Nannomonas) and Trypanosoma vivax (subgenusDutonella) are transmitted by tsetse flies (Glossina species) and remain the two main
causative agents of African animal trypanosomosis (AAT), resulting in estimated eco-
nomic losses of between $1 billion and $5 billion per annum throughout sub-Saharan
Africa (1). Other causes of animal trypanosomosis include Trypanosoma evansi, T.
equiperdum, and, to some extent, T. brucei brucei. Like T. evansi (which is found
worldwide and which causes the disease surra), T. vivax is also found outside the African
tsetse fly belt, adapting itself well to the South American continent via mechanical
transmission. The chemotherapeutic treatment surrounding the control of T. congo-
lense and T. vivax infections (nagana in cattle) within Africa has relied predominantly on
three drugs, namely, diminazene diaceturate, homidium chloride, and isometamidium
chloride; isometamidium chloride is often administered prophylactically, as well as for
the treatment of infections. Numerous reports (2–7) have clearly demonstrated that
drug resistance has become a serious hindrance to the effective control of AAT in Africa.
With such a small repertoire of potential drugs, limited success with the production of
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vaccines for use in the future, and the continued movement of animals to and from
tsetse fly-infested areas, alternative chemotherapeutic agents are urgently required.
The activities and efficacies of diamidine (dicationic) compounds against a panel of
different kinetoplastid parasites have previously been investigated (8–10), and these
compounds have been demonstrated to have good efficacy against a variety of
pathogens (11). Diamidines were also investigated for their in vitro activities and
efficacies against T. evansi in animal models (12–14). With such promising data, it
seemed appropriate to ascertain the potential activity that related diamidines (and their
analogues) could exert against T. congolense and T. vivax. A selection of compounds
was made on the basis of the in vitro activities of the compounds against T. brucei-
related species found previously (8, 13). Hence, the aim of this study was to evaluate the
in vitro, ex vivo, and in vivo (mouse) efficacies of 37 diamidine compounds against both
T. congolense and T. vivax strains.
RESULTS
In total, the activities of two standard drugs and 37 diamidine compounds against
a susceptible T. congolense strain (IL-3000) were investigated in vitro. The 50% inhibitory
concentrations (IC50s; in micrograms per milliliter) of each compound were obtained for
three separate assay incubation times: 40, 48, and 72 h. These IC50s are shown in Table
1, together with those of the two standard drugs, diminazene aceturate and isomet-
amidium chloride. In summary, the in vitro IC50s of the standard drugs for IL-3000 for
assay incubation times of 40, 48, and 72 h were observed to be 0.278, 0.076, and 0.066
g/ml, respectively, for diminazene and 0.0014, 0.0004, and 0.0003 g/ml, respectively,
for isometamidium. The IC50s of the 37 diamidine compounds ranged from 0.039 to
2.721 g/ml for the 40-h assay, from 0.010 to 0.875 g/ml for the 48-h assay, and from
0.007 to 0.562 g/ml for the 72-h assay. In general, the IC50s consistently decreased as
the incubation time increased. A similar trend was seen for the two standard drugs
diminazene and isometamidium. The influence of the incubation time on the IC50
results could clearly be seen across the 40-, 48-, and 72-h in vitro assays with T.
congolense. The IC50s did not differ greatly between the 48- and 72-h in vitro assays with
T. congolense, with 31 of the 37 compounds tested showing less than 2-fold decreases
in their IC50s. Furthermore, the remaining 6 of the 37 compounds tested showed less
than a 3-fold decrease in their IC50s. In contrast, the IC50s produced in the 40- and 72-h
in vitro assays with T. congolense demonstrated a much wider range, with an up to
8-fold decrease in IC50s being seen between the 40- and 72-h assay durations.
In comparison, all 37 diamidine compounds and the two standard drugs were
investigated ex vivo using T. congolense (STIB 736/IL-1180) and T. vivax (STIB 719/ILRAD
560) strains, neither of which is currently adapted to axenic culture conditions. The ex
vivo assay was adapted from the [3H]hypoxanthine incorporation assay (15) and was
performed at 40 h for all compounds. The IC50s obtained for both strains are shown in
Table 1. The ex vivo IC50s of the standards, diminazene and isometamidium, against
both parasite strains were similar, namely, 0.095 and 0.0004 g/ml, respectively, for T.
congolense and 0.076 and 0.0008 g/ml, respectively, for T. vivax. The IC50s of the 37
diamidine compounds tested against T. congolense ranged from 0.012 to 1.793 g/ml,
whereas the IC50s against T. vivax ranged from 0.019 to 0.607 g/ml. The IC50s obtained
for T. vivax were generally lower than those obtained for the T. congolense strain.
Subsequently, diminazene and isometamidium, together with 33 of the original 37
diamidine compounds, were further investigated for their in vivo efficacies against T.
congolense and T. vivax in mouse models of infection. Four diamidine compounds had
to be excluded from the in vivo experiments due to the discontinuation of product
availability. The in vivo efficacy and the results of dose-response assays in which
infected mice were intraperitoneally (i.p.) treated with the compounds on 4 consecutive
days are shown in Table 2. For diminazene, 100% of T. congolense-infected mice were
cured by doses of 20, 10, and 5 mg/kg of body weight given i.p. on 4 consecutive days,
but only 75% (3/4) could be cured by a dose of 2.5 mg/kg. In comparison, 100% of T.
vivax-infected mice could be cured only with a diminazene dose of 20 mg/kg given i.p.
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on 4 consecutive days, while only 2/4 mice (50%) could be cured at doses of 10, 5, and
2.5 mg/kg. The minimal curative doses of isometamidium in T. congolense- and T.
vivax-infected mice were observed to be 0.03125 mg/kg and 0.0625 mg/kg, respec-
tively, when the drug was given i.p. on 4 consecutive days.
In summary, 16 of the 33 diamidine compounds investigated were found to provide
a full cure (4/4) in T. congolense-infected mice when they given at the 5-mg/kg dose i.p.
on 4 consecutive days. Eleven of the 33 diamidine compounds tested were found to
provide at least a 75% curative efficacy (3/4) at the 2.5-mg/kg dose, and just 3 of the
33 diamidine compounds tested were found to be at least 75% curative when they
were given at the 1.25-mg/kg dose i.p. on 4 consecutive days. In comparison, 15 of the
33 diamidine compounds investigated were found to provide a full cure (4/4) in T.
vivax-infected mice when they were given at the 5-mg/kg dose i.p. on 4 consecutive
days. Just 7 of the 33 diamidine compounds tested were found to provide at least 75%
curative efficacy (3/4) when they were given at the 2.5-mg/kg dose, and just 4 of the
33 diamidine compounds tested were found to be at least 75% curative (3/4) when they
TABLE 1 In vitro and ex vivo IC50s of two standard drugs and 37 novel diamidine compounds for T. congolense and T. vivax strains for
various assay incubation times
Compound identity Chemical family
IC50 (g/ml)
In vitro assays with T. congolense
IL-3000 Ex vivo assays
40 h 48 h 72 h
T. congolense
STIB 736 (40 h)
T. vivax
STIB 719 (40 h)
Diminazene Triazene diamidine 0.278 0.076 0.066 0.095 0.076
Isometamidium Triazene amidine 0.0014 0.0004 0.0003 0.0004 0.0008
DB 75 Diphenylfuran 0.327 0.146 0.084 0.166 0.068
DB 283 Diphenylpyrimidine 0.842 0.225 0.187 0.212 0.100
DB 320 Diphenylpyrrole 0.532 0.218 0.200 0.210 0.139
DB 346 Biphenyl 0.119 0.061 0.036 0.041 0.048
DB 820 Pyridylfuran 0.316 0.203 0.187 0.206 0.195
DB 829 Pyridylfuran 0.510 0.204 0.198 0.212 0.166
DB 867 Pyridylfuran 0.258 0.179 0.173 0.222 0.062
DB 1052 Thiazole 1.725 0.533 0.562 0.815 0.607
DB 1055 Benzimidazole 0.373 0.115 0.051 0.053 0.040
DB 1192 Indole 0.244 0.088 0.069 0.091 0.073
DB 1307 Thiophene 0.465 0.209 0.188 0.247 0.089
DB 1406 Diphenylpyrimidine 0.698 0.216 0.197 0.259 0.147
DB 1854 Indole 0.039 0.010 0.007 0.012 0.032
DB 1866 Thiophene 0.086 0.021 0.019 0.053 0.019
DB 1870 Indole 0.087 0.019 0.019 0.058 0.066
DB 1893 Indole 0.204 0.062 0.058 0.089 0.178
DB 1903 Indole 0.261 0.060 0.033 0.044 0.023
DB 1915 Biphenylbenzanilide 0.476 0.187 0.065 0.101 0.074
DB 1917 Biphenylbenzanilide 2.721 0.729 0.420 1.193 0.032
DB 2017 Thiazolothiazole 0.094 0.040 0.034 0.016 0.101
DB 2175 Diphenylether 0.505 0.208 0.169 0.236 0.114
DB 2179 Bifuran 0.685 0.237 0.194 0.190 0.031
DB 2180 Selenophene 0.445 0.144 0.177 0.363 0.105
DB 2190 Thiazole 0.520 0.183 0.153 0.175 0.155
7 SAB 038 Benzofuran 0.198 0.074 0.059 0.084 0.052
10 SAB 078 Benzofuran 2.623 0.875 0.413 1.793 0.130
12 SAB 081 Benzofuran 0.623 0.220 0.118 0.703 0.062
13 SAB 017 Benzofuran 0.272 0.122 0.067 0.080 0.040
13 SAB 089 Benzimidazole 0.139 0.073 0.026 0.035 0.027
16 DAP 095 Isoxazole 0.309 0.155 0.072 0.220 0.071
17 SAB 085 Triazole 0.116 0.051 0.052 0.166 0.121
18 SAB 023 Triazole 0.426 0.186 0.174 0.241 0.153
19 DAP 025 Naphthylene 0.336 0.197 0.130 0.215 0.189
24 SMB 001 Dithiophene 0.184 0.124 0.066 0.070 0.048
27 DAP 060 Dipyridylphenyl 0.248 0.147 0.068 0.222 0.176
28 DAP 010 Dipyridylphenyl 0.606 0.226 0.195 0.586 0.089
32 DAP 022 Pyridyloxazole 0.071 0.027 0.016 0.043 0.033
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TABLE 2 In vivo efficacy and dose-response for two standard drugs and 33 novel diamidine compounds given on 4 consecutive days i.p.
in mouse models of T. congolense and T. vivax infection
Compound identity
Dose tested
(mg/kg)
T. congolense (STIB 736/IL-1180) T. vivax (STIB 719/ILRAD 560)
Chemical
structure
No. of mice
cured/no. infected
Relapse
daya
No. of mice cured/no.
of mice infected
Relapse
day
Diminazene 20 4/4 NAb 4/4 NA
10 4/4 NA 2/4 40
5 4/4 NA 2/4 6
2.5 3/4 11 2/4 1
Isometamidium 0.0625 4/4 NA 4/4 NA
Cl0.03125 4/4 NA 0/4 7
0.015625 3/4 41 0/4 7
DB 75 5 4/4 NA 4/4 NA
2.5 3/4 14 4/4 NA
1.25 2/4 4 4/4 NA
0.625 0/4 4 0/4 2
DB 283 5 0/4 2 3/4 17
DB 320 5 0/4 11 1/4 6
DB 346 5 0/4 12 0/4 2
DB 820 2.5 4/4 NA 4/4 NA
1.25 2/4 8 4/4 NA
0.625 0/4 1 0/4 1
DB 829 1.25 4/4 NA 4/4 NA
0.625 0/4 3 0/4 1
DB 867 5 4/4 NA 4/4 NA
2.5 4/4 NA 0/4 3
1.25 3/4 8 0/4 1
DB 1052 5 0/4 3 2/4 9
DB 1055 5 0/4 5 0/4 7
DB 1192 5 0/4 7 0/4 9
DB 1307 5 0/4 1 0/4 7
(Continued on next page)
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TABLE 2 (Continued)
Compound identity
Dose tested
(mg/kg)
T. congolense (STIB 736/IL-1180) T. vivax (STIB 719/ILRAD 560)
Chemical
structure
No. of mice
cured/no. infected
Relapse
daya
No. of mice cured/no.
of mice infected
Relapse
day
DB 1406 5 4/4 NA 4/4 NA
2.5 0/4 10 4/4 NA
1.25 0/4 1 2/4 12
DB 1854 5 4/4 NA 4/4 NA
2.5 3/4 44 2/4 18
DB 1866 5 2/4 9 1/4 11
DB 1870 5 4/4 NA 0/4 7
2.5 4/4 NA 0/4 3
1.25 3/4 15 0/4 1
DB 1893 5 4/4 NA 1/4 10
2.5 4/4 NA 0/4 2
1.25 0/4 5 0/4 1
DB 1903 5 0/4 6 0/4 3
DB 1917 5 0/4 2 3/4 10
DB 2017 5 0/4 2 0/4 1
DB 2190 5 2/4 15 0/4 6
7 SAB 038 5 4/4 NA 4/4 NA
2.5 3/4 11 2/4 21
10 SAB 078 5 0/4 3 0/4 3
12 SAB 081 5 0/4 8 4/4 NA
2.5 0/4 1 4/4 NA
1.25 0/4 1 3/4 39
13 SAB 017 5 4/4 NA 4/4 NA
2.5 0/4 12 0/4 11
(Continued on next page)
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were given at the 1.25-mg/kg dose i.p. on 4 consecutive days. The compound providing
100% curative efficacy for both T. congolense- and T. vivax-infected mice when it was
given at the minimal curative dose of 1.25 mg/kg i.p. on 4 consecutive days was
compound DB 829.
Consequently, the two standard drugs and 15 of the 33 diamidine compounds
previously tested in vivo were additionally examined for their curative efficacy when
they were given to T. congolense- and T. vivax-infected mice as a single bolus treatment
dose i.p. The resulting in vivo efficacy data can be viewed in Table 3. The minimal dose
showing a 100% curative efficacy of diminazene against both parasites when it was
given i.p. as a single bolus dose was observed to be 10 mg/kg. A single bolus dose of
5 mg/kg given i.p. was found to have insufficient efficacy (1/4 or 0/4) against both
trypanosome species. For isometamidium, the minimal curative dose showing a 100%
rate of cure for T. congolense- and T. vivax-infected mice was 0.25 mg/kg given i.p. A
single bolus dose of 0.125 mg/kg given i.p. cured 3 out of 4 T. vivax-infected mice but
only 1 out of 4 T. congolense-infected mice.
In summary, 4 of the 15 diamidine compounds evaluated were found to provide the
full cure (4/4) of both T. congolense- and T. vivax-infected mice when given as a single
bolus dose of 10 mg/kg i.p. Two of the 15 diamidine compounds tested were found to
provide at least a 75% cure (3/4) of both T. congolense- and T. vivax-infected mice when
TABLE 2 (Continued)
Compound identity
Dose tested
(mg/kg)
T. congolense (STIB 736/IL-1180) T. vivax (STIB 719/ILRAD 560)
Chemical
structure
No. of mice
cured/no. infected
Relapse
daya
No. of mice cured/no.
of mice infected
Relapse
day
13 SAB 089 5 4/4 NA 4/4 NA
2.5 3/4 18 4/4 NA
1.25 1/4 5 0/4 9
16 DAP 095 5 2/4 14 4/4 NA
2.5 0/4 10 2/4 16
17 SAB 085 5 4/4 NA 1/4 2
2.5 4/4 NA 0/4 1
1.25 0/4 1 0/4 1
18 SAB 023 5 4/4 NA 4/4 NA
2.5 0/4 12 3/4 7
19 DAP 025 5 4/4 NA 4/4 NA
2.5 0/4 8 0/4 9
24 SMB 001 5 0/4 6 4/4 NA
2.5 0/4 1 0/4 5
27 DAP 060 5 4/4 NA 4/4 NA
2.5 0/4 8 0/4 4
28 DAP 010 5 3/4 38 3/4 9
2.5 3/4 15 0/4 7
32 DAP 022 5 4/4 NA 2/4 10
2.5 2/4 28 0/4 5
aRelapse day, the day on which the mice were monitored, beginning from the day after final drug administration.
bNA, not applicable, as no relapse was seen during the complete 60-day monitoring phase.
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TABLE 3 In vivo efficacy and dose-response for two standard drugs and 15 novel diamidine compounds given as a single bolus dose i.p.
in mouse models of T. congolense and T. vivax infection
Compound identity
Dose tested
(mg/kg)
T. congolense (STIB 736/IL-1180) T. vivax (STIB 719/ILRAD 560)
Chemical
structure
No. of mice
cured/no. infected
Relapse
daya
No. of mice
cured/no. infected Relapse day
Diminazene 20 4/4 NAb 4/4 NA
10 4/4 NA 4/4 NA
5 1/4 11 0/4 6
2.5 0/4 12 0/4 1
Isometamidium 1 4/4 NA 4/4 NA
0.5 4/4 NA 4/4 NA
0.25 4/4 NA 4/4 NA
0.125 1/4 11 3/4 14
0.0625 0/4 8 0/4 6
DB 75 10 4/4 NA 4/4 NA
5 4/4 NA 4/4 NA
2.5 0/4 6 4/4 NA
1.25 0/4 1 0/4 7
DB 820 10 4/4 NA 4/4 NA
5 0/4 10 1/4 19
DB 829 10 4/4 NA 4/4 NA
5 3/4 14 3/4 7
DB 867 10 4/4 NA 0/4 7
5 0/4 8 0/4 1
DB 1406 10 4/4 NA 4/4 NA
5 0/4 3 0/4 3
DB 1854 10 2/4 8 2/4 4
5 2/4 1 2/4 1
DB 1870 10 4/4 NA 2/4 14
5 3/4 33 1/4 3
2.5 0/4 11 0/4 1
DB 1893 10 4/4 NA 2/4 7
5 0/4 10 0/4 2
7 SAB 038 10 0/4 11 2/4 17
5 0/4 4 2/4 5
12 SAB 081 10 0/4 1 4/4 NA
5 0/4 1 4/4 NA
2.5 0/4 1 4/4 NA
1.25 0/4 1 0/4 3
13 SAB 089 10 0/4 8 2/4 10
5 0/4 6 2/4 5
(Continued on next page)
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they were given as a single bolus dose of 5 mg/kg i.p. None of the diamidine
compounds tested were found to provide a cure when they were given to T.
congolense-infected mice as a single bolus dose of 2.5 mg/kg i.p. However, 2 of the 15
diamidine compounds were found to be 100% curative when they were given to T.
vivax-infected mice as a single bolus dose of 2.5 mg/kg. The minimal curative doses
providing 100% cure of T. congolense- and T. vivax-infected mice were therefore single
bolus doses of 5 and 2.5 mg/kg given i.p., respectively.
DISCUSSION
The aim of this study was to determine the activities of diamidine compounds (and
their analogues) against the animal-pathogenic parasites Trypanosoma congolense and
T. vivax. By leveraging such chemical classes of molecules, previously found to be
efficacious against a variety of similar kinetoplastid organisms, and the in-depth knowledge
already gained from such investigations, the pursuit of more effective, alternative
chemotherapeutic agents for the treatment of nagana can efficiently be explored. Both
T. congolense and T. vivax originate from subgenera different from those of other
trypanosome species, such as T. brucei brucei, T. brucei rhodesiense, and T. evansi. The
current inability to continuously culture bloodstream forms of T. vivax under full axenic
conditions still presents a severe hindrance to the accurate evaluation of new potential
chemotherapeutic molecules with activities against these organisms. By establishing an
ex vivo hypoxanthine assay for determination of the drug sensitivity of T. vivax with
optimized assay duration, trypanosome concentration, and temperature parameters,
the first reported set of novel compounds with activities against the bloodstream forms
of T. vivax according to IC50s indicating susceptibility has been achieved. Work is
already under way to improve this ex vivo approach by establishing a stable and
reproducible alamarBlue assay for the drug sensitivity of T. vivax, which will enhance
the time efficiency and cost-effectiveness of the current ex vivo hypoxanthine test for
drug susceptibility.
Diamidines are known to take 48 to 72 h to fully exert their biological and
chemotherapeutic potency, so the decrease in the IC50s for T. congolense IL-3000
obtained across the 40-, 48-, and 72-h alamarBlue assays was expected. This trend was
similarly observed for the standard drugs diminazene (a diamidine) and isometamidium
(an amidine). In comparison, the IC50s for T. congolense STIB 736/IL-1180 determined in
the ex vivo assays were lower than the IC50s determined in the in vitro assays for. Both
assays used incubation times of 40 h. The [3H]hypoxanthine assay could be run only for
TABLE 3 (Continued)
Compound identity
Dose tested
(mg/kg)
T. congolense (STIB 736/IL-1180) T. vivax (STIB 719/ILRAD 560)
Chemical
structure
No. of mice
cured/no. infected
Relapse
daya
No. of mice
cured/no. infected Relapse day
18 SAB 023 10 0/4 9 4/4 NA
5 0/4 8 2/4 1
19 DAP 025 10 1/4 8 2/4 17
5 0/4 7 2/4 7
28 DAP 010 10 2/4 12 4/4 NA
5 0/4 8 0/4 3
32 DAP 022 10 1/4 15 0/4 7
5 0/4 8 0/4 2
aRelapse day, the day on which the mice were monitored, beginning from the day after final drug administration.
bNA, not applicable, as no relapse was seen during the complete 60-day monitoring phase.
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40 h, since at 48 and 72 h the parasites were no longer viable. Neither T. congolense STIB
736/IL-1180 nor T. vivax STIB 719/ILRAD 560 is adapted to axenic culture and thus can
be maintained in culture medium only for up to 42 h. Nevertheless, the IC50s for both
STIB 736/IL-1180 and STIB 719/ILRAD 560 obtained at 40 h in the ex vivo assays
correlated well with those obtained for T. congolense IL-3000 in the alamarBlue assay.
Since the target animals for an alternative chemotherapeutic agent for the treat-
ment of nagana are ruminants, in particular, cattle, the desired drug candidate should
be able to be administered effectively via the intramuscular (i.m.) route. In mouse
models of infection, i.m. administration is rather cumbersome; therefore, an i.p. route of
compound administration was used. Two of the standard drugs, diminazene and
isometamidium, were assessed separately in established mouse models of T. congolense
and T. vivax infection to determine their effectiveness. Once a reference profile for the
standard drugs was established, the diamidine molecules were comparatively assessed
for their curative potential on the basis of a 4-day consecutive treatment schedule. The
ideal target product profile (TPP) of a new drug for the treatment of nagana should
have an optimized treatment regimen, preferably with a single application, since a
4-day treatment schedule would be impractical for rural field settings. Consequently,
the top 15 most efficacious diamidines identified in the 4-day treatment schedule in the
in vivomouse models were further examined by application of only a single bolus dose.
Special attention has to be given to the problem of cross-resistance to the standard
drugs diminazene aceturate (a diamidine) and isometamidium (an amidine). New
diamidines have to be able to overcome this cross-resistance. This could be shown by
using the knockout line T. brucei AT1 (which is missing the transporter responsible for
the uptake of many diamidines), which showed a level of sensitivity to several diami-
dines comparable to that of a reference T. b. rhodesiense strain and a drug-sensitive T.
evansi strain (13). The use of drug-resistant T. congolense and T. vivax isolates should be
envisaged for any further studies with diamidine molecules.
In summary, the process described here highlights that the following compounds
are potential candidates for evaluation in preclinical studies as treatments for infections
caused by (i) both T. congolense and T. vivax trypanosome species (DB 75, DB 820, DB
829, DB 1406, 19 DAP 025, 28 DAP 010, and 13 SAB 089), (ii) T. congolense only (DB 867,
DB 1854, DB 1870, DB 1893, 17 SAB 085 and 32 DAP 022), and (iii) T. vivax only (12 SAB
081 and 18 SAB 023). Having identified several lead diamidines in this study, the next
step will be to investigate these compounds in a ruminant (e.g., goat) model of
infection to assess their viability as candidates for the clinical treatment of T. congolense
and T. vivax infections. Cross-resistance should also be investigated by employing
drug-resistant isolates of T. congolense and T. vivax.
MATERIALS AND METHODS
Trypanosome stocks. The IL-3000 T. congolense strain was originally derived from the Trans Mara I
strain, which was isolated from a bovine (within the Trans Mara region of Kenya) in 1966 (16). The IL-3000
derivative grows well as bloodstream forms in axenic culture and was thus used as the T. congolense
reference strain in all in vitro drug sensitivity assays in this study. The STIB 736/IL-1180 T. congolense strain
is a clone originally derived from the STIB 212 T. congolense strain, which was isolated from a lion in the
Serengeti National Park of Tanzania in 1971 (17). The STIB 736/IL-1180 strain was used for all ex vivo and
in vivo experiments performed with T. congolense in this study. Both T. congolense strains used in this
study belong to the savannah subgenotype family. The STIB 719/ILRAD 560 T. vivax strain originated from
the Y486 T. vivax strain, isolated from a naturally infected bovine in 1976 in Zaria, Nigeria (18). The Y486
T. vivax strain could be cultivated as bloodstream forms over a feeder layer (19), which is not appropriate
for drug-screening purposes. Axenic cultivation is still not possible today. To our knowledge, strains
derived from the T. vivax Y486 strain are the only T. vivax strains that can be successfully propagated in
rodent models and are representative of West African T. vivax strains. The STIB 719/ILRAD 560 T. vivax
strain was therefore used in all ex vivo and in vivo experiments carried out in this study.
Mice. Female NMRI mice weighing between 19 and 22 g were used for all in vivo experiments. Mice
were specific pathogen free (SPF) and were housed in standard Macrolon type II cages at 22°C with a
relative humidity of 60 to 70%. The mice received pelleted food and water ad libitum. All in vivo
experiments were carried out in compliance with the regulations set out by the Swiss Federal Veterinary
Office.
Standard trypanocidal drugs. Diminazene aceturate (catalog number D-7770; Sigma, St. Louis, MO,
USA), isometamidium chloride (Trypamidium-Samorin; Merial, France), and homidium chloride (No-
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vidium; Merial, France) were used as the standard trypanocidal drugs in the in vitro, ex vivo, and in vivo
experiments performed in this study.
Diamidine test compounds. All the diamidine test compounds investigated had previously been
synthesized in the laboratories of David W. Boykin (Georgia State University, Atlanta, GA, USA) and
Richard R. Tidwell (University of North Carolina, Chapel Hill, NC, USA) with the aim of obtaining structural
diversity, chemical stability, and a low cost of goods. For the in vivo experiments evaluating the activities
of the diamidine test compounds against T. congolense and T. vivax, the diamidine test compounds were
selected according to their previously demonstrated in vivo efficacies against T. brucei-related species
and their absence of acute toxicity in previous experiments (8, 12). All selected compounds showed
greater than 75% in vivo efficacy against T. b. rhodesiense or T. evansi and no acute in vivo toxicity at
cumulative doses of up to 100 mg/kg of body weight given intraperitoneally (i.p.); an exception to this
was the parent compound DB 75, where acute toxicity in mice was seen at a cumulative dose of 20
mg/kg of body weight given i.p.
Culture media. Bloodstream-form trypanosomes of T. congolense (IL-3000) were cultured in Iscove’s
modified Dulbecco’s medium (IMDM; catalog number I3390; Sigma, St. Louis, MO, USA) supplemented
with 3 g/liter NaHCO3 and 200 mM L-glutamine. The medium was then further supplemented by adding
1% of a 1.2 mM stock of 2-mercaptoethanol, 1% of a stock consisting of 5 mM bathocuproindisulfate, 150
mM L-cysteine HCl, 100 mM pyruvate, 50 mM hypoxanthine, 16 mM thymidine, and 20% heat-inactivated
bovine serum. The complete medium was used for T. congolense (IL-3000) cultivation, as well as for all
in vitro antitrypanosomal assay procedures. Bloodstream-form trypanosomes of non-culture-adapted T.
congolense (STIB 736/IL-1180) and T. vivax (STIB 719/ILRAD 560) were supported in IMDM (catalog
number I3390; Sigma, St. Louis, MO, USA) supplemented with 3 g/liter NaHCO3. The medium was then
further supplemented by adding 1% of a stock consisting of 5 mM bathocuproindisulfate, 150 mM
L-cysteine HCl, 100 mM pyruvate, 16 mM thymidine, 200 mM L-glutamine, and 20% heat-inactivated
bovine serum. The complete medium was used for all ex vivo [3H]hypoxanthine incorporation assays with
T. congolense and T. vivax.
Radioactive hypoxanthine. Radioactively labeled hypoxanthine ([8-3H]hypoxanthine; catalog num-
ber TRK74; Amersham Biosciences UK Limited, Buckinghamshire, United Kingdom) was used for the ex
vivo [3H]hypoxanthine (40-h) incorporation assays with T. congolense and T. vivax.
Stock solutions and dilutions. A 10-mg/ml stock solution was prepared for each compound
(dissolved in 100% dimethyl sulfoxide [DMSO]) and was stored frozen at 20°C. From these stock
solutions, further stock solutions and compound dilutions were made for use in the various in vitro T.
congolense cell viability assays and the T. congolense and T. vivax ex vivo incorporation assays using the
appropriate culture medium as a solvent. Compound dilutions were prepared fresh on the day of the
respective assays. For the in vivo mouse experiments, a 10-mg/ml stock solution was similarly prepared
for each diamidine test compound, which was dissolved in sterile distilled water, containing 10% DMSO.
Further dilutions depending on the dose being tested were made from these stock solutions. Stock
solutions and dilutions of the standard trypanocidal drugs were prepared in sterile distilled water. All
stock solutions and dilutions for the in vivo mouse experiments were made fresh on the day of
administration and for each individual in vivo experiment.
In vitro antitrypanosomal assay. The IC50s of the test compounds for T. congolense (IL-3000) were
determined using the alamarBlue assay (20), but with modified incubation times of 40, 48, and 72 h.
Trypanosome densities were calculated using a cell counter and analyzer system (CASY; Schärfe System,
Reutlingen, Germany), and the trypanosomes were diluted accordingly. Trypanosome seeding densities
of 2  105/ml, 1  105/ml, and 1  105/ml in culture medium were used for the 40-, 48-, and 72-h
alamarBlue assays, respectively. All assay plates were incubated at 34°C with 5% CO2 for the time period
being tested (24, 44, and 68 h), before the plates were removed from the incubator and 10 l of resazurin
dye (12.5 mg in 100 ml phosphate-buffered saline; catalog number 33934; Aldrich/Fluka, Buchs, Swit-
zerland) was added to each well. The plates were then further incubated for 16, 4, and 4 h respectively,
under the same conditions described above. Thereafter, the assay plates were read using a fluorescence
reader (SpectraMax, Gemini XS; Bucher Biotec, Basel, Switzerland) at excitation and emission wavelengths
of 536 and 588 nm, respectively. The data generated were analyzed using SOFTmax Pro software (version
5.2) to determine the IC50s. All in vitro experiments were performed in duplicate in three independent
assay runs for each compound.
Ex vivo [3H]hypoxanthine incorporation assay. The exact procedure for the ex vivo [3H]hypoxan-
thine incorporation assay has been described previously (15) but was slightly modified for use in this
study. Briefly, 50 l of culture medium containing no hypoxanthine was added to each well of a 96-well
microtiter plate, except for the first two and last two wells of the last column (to which 100 l was added
instead to act as a negative control) and all the wells in the first column. The drugs were applied at 75-l
volumes (containing two times the highest drug concentration) into the empty wells of the first column,
corresponding to the required starting concentration of each drug being tested. Thereafter, 25-l
volumes were removed from the first column using a multichannel pipette and mixed with the contents
in the wells in the next column. Again, 25 l was removed from the second column and placed into the
next column, and the contents were mixed several times. This step was repeated until the 11th column
was reached. The final 25 l from this 11th column was then discarded. This process created a 3-fold
serial drug dilution across the microtiter plate.
Cardiac puncture of a highly parasitemic NMRI (female) mouse that had previously been infected
with the corresponding T. congolense or T. vivax strain was performed. The blood collected was then
mixed with phosphate-buffered saline with glucose (PSG; 6:4) in a 1:2 ratio, and the mixture was
centrifuged for 12 min at 70 g to separate the blood cells from the trypanosomes. After centrifugation,
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the supernatant containing the trypanosomes was carefully transferred to a fresh tube, and the
trypanosome concentration was determined using a Neubauer chamber. The trypanosome density was
adjusted to provide starting concentrations of 2  106/ml and 2  105/ml for T. congolense and T. vivax,
respectively. A 50-l volume of this trypanosome suspension was then added to all 96 wells, with the
exception of the 4 negative-control wells in the last column. The plates were then incubated in a
humidified atmosphere containing 5% CO2 at 34°C for T. congolense or 37°C for T. vivax. After 24 h of
incubation, the plates were removed, and a solution of 1 Ci of radioactive hypoxanthine in 20 l of
culture medium was placed into each well. The plates were returned to the incubator for a further 16-h
incubation period under the same conditions described above. After a complete incubation time of 40
h, the plates were removed and the contents of the wells were harvested on glass fiber filters using a
96-well harvester (model 1290-004 Betaplate; Berthold Technologies GmbH, Regensdorf, Switzerland).
Thereafter, the radioactivity counts were measured using a liquid scintillation counter (model 1205
Betaplate; Berthold Technologies GmbH, Regensdorf, Switzerland). The data obtained were further
analyzed by transferring them into a standard operating protocol template in a graphics program
(Microsoft Excel) for determination of the IC50s. All ex vivo experiments were performed in duplicate in
three independent assay runs for each compound.
In vivo mouse efficacy experiments. NMRI (female) mice were arranged into groups of four before
being independently infected with either 105 or 104 parasites in 0.25 ml of PSG in a ratio of 6:4 for T.
congolense (STIB 736/IL-1180) or T. vivax (STIB 719/ILRAD 560), respectively. Infection in all experiments
was performed from stabilated blood, stored frozen in liquid nitrogen, using the i.p. route. For all
experiments of the efficacies of the compounds against T. congolense, a parasitemia of 106 per ml blood
was allowed to develop over 168 h (7 days), before treatment was administered i.p. on days 7 to 10
postinfection. Comparatively, for all experiments of the efficacies of the compounds against T. vivax, a
parasitemia of 106 per ml blood was allowed to develop over 72 h (3 days), before treatment was
administered i.p. on days 3 to 6 postinfection. Thereafter, the level of parasitemia in the mice was
monitored using a tail blood examination technique until day 60 posttreatment. This lengthy follow-up
period posttreatment was carried out to account for any possible relapses during the experiments.
Parasitemia was checked twice a week for the first month and then once per week for the remaining
month. Thereafter, any surviving and aparasitemic mice were considered cured. Untreated (control) mice
infected with T. congolense and T. vivax survived, on average, for 11 or 6 days postinfection, respectively.
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